Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028137 | 1.00 | LMNA (0.52) | LMNAPTPN1CDC25BTSHRAKT1 | |
| SCHEMBL7714704 | 0.86 | LMNA (0.38) | LMNAPTPN1CDC25B | |
| SCHEMBL7690022 | 0.86 | LMNA (0.38) | LMNAPTPN1CDC25B | |
| SCHEMBL14635989 | 0.80 | GRM2 (0.43) | — | |
| SCHEMBL6961092 | 0.79 | TDP1 (0.53) | TSHRDRD1L3MBTL1HRH3 | |
| SCHEMBL3142790 | 0.76 | LMNA (0.63) | LMNAPTPN1CDC25BTSHRAKT1 | |
| SCHEMBL11372268 | 0.75 | LMNA (0.50) | LMNAPTPN1CDC25BTSHRDRD1 | |
| SCHEMBL9269173 | 0.74 | LMNA (0.53) | LMNAPTPN1CDC25BTSHRAKT1 | |
| SCHEMBL25307508 | 0.73 | LMNA (0.55) | LMNAPTPN1CDC25BTSHRAKT1 | |
| SCHEMBL25306643 | 0.73 | LMNA (0.48) | LMNAPTPN1CDC25BTSHRDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638955-B2 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2003-10-28 | — | — | US | disclosed |
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | SYNGENTA LIMITED (GB) | 2002-09-19 | — | — | US | disclosed |
| US-6365751-B1 | ACTIVE AGAINST GRAM-POSITIVE BACTERIA, IN PARTICULAR, AGAINST STRAINS RESISTANT TO VANCOMYCIN, AMINOGLYCOSIDES AND PENCILLINS AND DERIVATIVES; NONTOXIC | ZENECA LTD. (GB) | 2002-04-02 | — | — | US | disclosed |
| US-6271383-B1 | USEFUL ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS; IN PARTICULAR, AGAINST VARIOUS STRAINS EXHIBITING RESISTANCE TO VANCOMYCIN AND AGAINST E. FAECIUM STRAINS RESISTANT TO BOTH AMINOGLYCOSIDES AND CLINICALLY USED BETA-LACTAMS. | ZENECA LIMITED (GB) | 2001-08-07 | — | — | US | disclosed |
| US-5981528-A | Antibiotic oxazolidinone derivatives | ZENECA LIMITED | 1999-11-09 | — | — | US | disclosed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133022-A1 | Antibiotic oxazolidinone derivatives | OXA1L, POLN, MRPL21 | LMNA 1055/4885PTPN1 2906/4885CDC25B 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.